Skip to main content
SpringerLink
Log in

Genital Herpes Simplex Virus Infection in the Adolescent

Special Considerations for Management

  • Therapy In Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Genital herpes simplex virus (HSV) infections are increasingly common among adolescents. In developed countries, during the 1990s, adolescent HSV type 2 seroprevalence rates ranged from 4 to 30% depending on the population studied. The clinical diagnosis of genital herpes may be unreliable and laboratory testing is recommended.

Aciclovir, valaciclovir, and famciclovir are three antiviral drugs that have proven efficacy in the treatment of genital herpes. These drugs can be used in the treatment of the first episode or for recurrent infections, or can be used long term to suppress recurrent infections. Once or twice daily administration regimens are preferable for adolescents for reasons of adherence, and because it avoids the need to take medication at school. Unproven remedies are used commonly and can be harmful.

In addition to antiviral therapy, proper management of the adolescent with genital herpes should also include developmentally appropriate explanations of the diagnosis, treatment and potential complications, recommendations for symptomatic relief, screening for other sexually transmitted infections, and discussion of safer sexual practices. All adolescents should have follow-up visits to complete education and counseling and to assess compliance with antiviral therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex virases 1 and 2. In: Evans AS, Kaslow RA, editors. Viral infection of humans: epidemiology and control. 4th ed. New York: Plenum Press, 1997: 419–54

    Google Scholar 

  2. Stanberry LR, Rosenthal SL. The epidemiology of herpes simplex virus infections in adolescents. Herpes 1999; 6: 12–5

    Google Scholar 

  3. Stanberry LR. The pathogenesis of herpes simplex viras infections. In: Stanberry LR, editor. Genital and neonatal herpes. London: John Wiley and Sons Ltd, 1996: 31–48

    Google Scholar 

  4. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 34: 1432–8

    Article  Google Scholar 

  5. Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994; 121: 847–54

    PubMed  CAS  Google Scholar 

  6. Stanberry L, Cunningham A, Mertz G, et al. New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res 1999; 42: 1–14

    Article  PubMed  CAS  Google Scholar 

  7. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337: 1105–11

    Article  PubMed  CAS  Google Scholar 

  8. Suligoi B, Cusan M, Santopadre P, et al. HSV-2 specific seroprevalence among various populations in Rome, Italy. The Italian Herpes Management Forum. Sex Transm Infect 2000; 76: 213–4

    Article  PubMed  CAS  Google Scholar 

  9. Vyse AJ, Gay NJ, Slomka MJ, et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Infect 2000; 76: 183–7

    Article  PubMed  CAS  Google Scholar 

  10. Wutzler P, Doerr HW, Farber I, et al. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations: relevance for the incidence of genital herpes. J Med Virol 2000; 61: 201–7

    Article  PubMed  CAS  Google Scholar 

  11. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116: 197–202

    PubMed  CAS  Google Scholar 

  12. Becker TM, Lee F, Daling JR, et al. Seroprevalence of and risk factors for antibodies to herpes simplex viruses, hepatitis B, and hepatitis C among southwestern hispanic and non-hispanic white women. Sex Transm Dis 1996; 23: 138–44

    Article  PubMed  CAS  Google Scholar 

  13. Rosenthal SL, Stanberry LR, Biro FM, et al. Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 1997; 24: 135–9

    Article  PubMed  CAS  Google Scholar 

  14. Bunnell RE, Dahlberg L, Rolfs R, et al. High prevalence and incidence of sexually transmitted diseases in urban adolescent females despite moderate risk behaviors. J Infect Dis 1999; 180: 1624–31

    Article  PubMed  CAS  Google Scholar 

  15. Huerta K, Berkelhamer S, Klein J, et al. Epidemiology of herpes simplex virus type 2 infections in a high-risk adolescent population. J Adolesc Health 1996; 18: 384–6

    Article  PubMed  CAS  Google Scholar 

  16. Sucato G, Celum C, Dithmer D, et al. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. Pediatr Infect Dis 2001; 20: 422–6

    Article  CAS  Google Scholar 

  17. Noell J, Rohde P, Ochs L, et al. Incidence and prevalence of chlamydia, herpes, and viral hepatitis in a homeless adolescent population. Sex Transm Dis 2001; 28: 4–10

    Article  PubMed  CAS  Google Scholar 

  18. Lewis LM, Bernstein DI, Rosenthal SL, et al. Seroprevalence of herpes simplex virus type 2 in African-American college women. J Natl Med Assoc 1999; 91: 210–2

    PubMed  CAS  Google Scholar 

  19. Cunningham AL, Lee FK, Ho DWT, et al. Herpes simplex virus type 2 antibody in patients attending antenatal or STD clinics. Med J Aust 1993; 158: 525–8

    PubMed  CAS  Google Scholar 

  20. Patrick DM, Dawar M, Cook DA, et al. Antenatal seroprevalence of herpes simplex virus type 2 (HSV-2) in Canadian women: HSV-2 prevalence increases throughout the reproductive years. Sex Transm Dis 2001; 28: 424–8

    Article  PubMed  CAS  Google Scholar 

  21. Abuharfeil N, Meqdam MM. Seroepidemiologic study of herpes simplex virus type 2 and cytomegalovirus among young adults in northern Jordan. New Microbiol 2000; 23: 235–9

    PubMed  CAS  Google Scholar 

  22. Perkins NL, Coughlan EP, Franklin RA, et al. Seroprevalence of herpes simplex virus type 2 antibodies in New Zealand sexual health clinic patients. NZ Med J 1996; 109: 402–5

    CAS  Google Scholar 

  23. Gil A, Gonzalez A, Dal-Re R, et al. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. J Infect 1998; 36: 53–6

    Article  PubMed  CAS  Google Scholar 

  24. Persson K, Mansson A, Jonsson E, et al. Decline of herpes simplex virus type 2 and chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern. Scand J Infect Dis 1995; 27: 195–9

    Article  PubMed  CAS  Google Scholar 

  25. Christie SN, McCaughey C, McBride M, et al. Herpes simplex type 1 and genital herpes in Northern Ireland. Int J STD AIDS 1997; 8: 68–9

    Article  PubMed  CAS  Google Scholar 

  26. Wald A, Benedetti J, Davis G, et al. A randomized, double-blind, comparative trial comparing high and standard dose oral acyclovir for first-episode genital herpes infections. Antimicrob Agents Chemother 1994; 38: 174–6

    Article  PubMed  CAS  Google Scholar 

  27. Lowhagen GB, Tunback P, Andersson K, et al. First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Infect 2000; 76: 179–82

    Article  PubMed  CAS  Google Scholar 

  28. Nilsen A, Myrmel H. Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand 2000; 79: 693–6

    PubMed  CAS  Google Scholar 

  29. Efstathiou S, Field HJ, Griffiths PD, et al. Herpes simplex virus latency and nucleoside analogues. Antiviral Res 1999; 41: 85–100

    Article  PubMed  CAS  Google Scholar 

  30. O’Brien JJ, Campoli-Richards DM. Aciclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989; 37: 233–309

    Article  PubMed  Google Scholar 

  31. Burnette TC, Harrington JA, Reardon JE, et al. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem 1995; 270: 15827–31

    Article  PubMed  CAS  Google Scholar 

  32. Perry CM, Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections. Drugs 1996; 52: 754–72

    Article  PubMed  CAS  Google Scholar 

  33. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993; 4Suppl. 1: 47–55

    CAS  Google Scholar 

  34. Centers for Disease Control and Prevention. CDC 1998 guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998; 47: 1–118

    Google Scholar 

  35. Peacock Jr JE, Kaplowitz LG, Sparling PF, et al. Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am J Med 1988; 85: 301–6

    Article  PubMed  Google Scholar 

  36. Corey L, Benedetti J, Critchlow C, et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983; 12Suppl. B: 79–88

    Article  PubMed  Google Scholar 

  37. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996; 276: 44–9

    Article  PubMed  CAS  Google Scholar 

  38. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind randomized clinical trial. Sex Transm Dis 1997; 24: 481–6

    Article  PubMed  CAS  Google Scholar 

  39. Benedetti JK, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1995; 121: 847–54

    Google Scholar 

  40. Reeves WC, Corey L, Adams HG, et al. Risk of recurrence after first episodes of genital herpes: relation to HSV type and antibody response. N Engl J Med 1981; 304: 315–9

    Article  Google Scholar 

  41. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus acyclovir in patient-initiated treatment of recurrent genital herpes: a randomized, double-blind clinical trial. Genitourin Med 1997; 73: 110–6

    PubMed  CAS  Google Scholar 

  42. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984; 251: 2103–7

    Article  PubMed  CAS  Google Scholar 

  43. Spruance S, Trying S, Degregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Arch Int Med 1996; 156: 1729–35

    Article  CAS  Google Scholar 

  44. Saiag P, Praindhui D, Chastang C. A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group. J Antimicrob Chemother 1999; 44(4): 525–31

    Article  PubMed  CAS  Google Scholar 

  45. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch Intern Med 1997; 157: 343–9

    Article  PubMed  CAS  Google Scholar 

  46. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once-daily therapy. Genitourin Med 1997; 73: 105–9

    PubMed  CAS  Google Scholar 

  47. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA 1998; 280: 887–92

    Article  PubMed  CAS  Google Scholar 

  48. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998; 178: 603–10

    Article  PubMed  CAS  Google Scholar 

  49. Carney O, Ross E, Ikkos G, et al. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993; 69: 457–9

    PubMed  CAS  Google Scholar 

  50. Patel R, Tyring S, Strand A, et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999; 75: 398–402

    Article  PubMed  CAS  Google Scholar 

  51. Sacks SL, Hughes A, Rennie B, et al. Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: a randomized, double-blind, double dummy, parallel group, placebo-controlled trial. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

  52. Sacks SL, Shafran SD. BID famciclovir suppression of asymptomatic genital herpes simplex virus shedding in men. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego

  53. Wald A, Warren T, Hu H, et al. Suppression of subclinical shedding of herpes simplex virus type 2 in the genital tract with valacyclovir. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego

  54. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Int Med 1996; 124: 8–15

    PubMed  CAS  Google Scholar 

  55. Mindel A, Carney O, Freris M, et al. Dosage and safety of long term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988; I: 926–8

    Article  Google Scholar 

  56. Goldberg LH, Kaufman R, Kurtz T, et al. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch Dermatol 1993; 129: 582–7

    Article  PubMed  CAS  Google Scholar 

  57. Fife KH, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir. J Infect Dis 1994; 169: 1338–41

    Article  PubMed  CAS  Google Scholar 

  58. Stanberry LR. Understanding herpes. Jackson (MI): University Press of Mississippi, 1998

    Google Scholar 

  59. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285: 3100–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

In preparing this manuscript, the author was supported, in part, by a National Institutes of Health Grant A137940; HD40151.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Texas Medical Branch, 3.300 Children’s Hospital, 301 University Boulevard, Galveston, Texas, 77555-0351, USA

    Lawrence R. Stanberry & Susan L. Rosenthal

Authors
  1. Lawrence R. Stanberry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan L. Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence R. Stanberry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stanberry, L.R., Rosenthal, S.L. Genital Herpes Simplex Virus Infection in the Adolescent. Pediatr-Drugs 4, 291–297 (2002). https://doi.org/10.2165/00128072-200204050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204050-00002

Keywords

Search

Navigation